Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 636

1.

[Comparative genomic classification of human hepatocellular carcinoma].

Kaposi-Novák P.

Magy Onkol. 2009 Mar;53(1):61-7. doi: 10.1556/MOnkol.53.2009.1.9. Hungarian.

2.

[Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].

Wu FS, Zheng SS, Wu LJ, Ding W, Ma ZM, Wang ZM, Teng LS, Zhao WH.

Zhonghua Wai Ke Za Zhi. 2006 May 1;44(9):603-8. Chinese.

PMID:
16784653
3.

Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.

Daveau M, Scotte M, François A, Coulouarn C, Ros G, Tallet Y, Hiron M, Hellot MF, Salier JP.

Mol Carcinog. 2003 Mar;36(3):130-41.

PMID:
12619035
5.

Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.

Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS.

Gastroenterology. 2004 May;126(5):1374-86.

PMID:
15131798
6.

Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis.

Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, Liu HL.

Br J Cancer. 2004 Jun 14;90(12):2349-55.

7.

Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.

Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E.

Hepatology. 1997 Apr;25(4):862-6.

PMID:
9096589
8.
9.

c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis.

Abou-Elella A, Gramlich T, Fritsch C, Gansler T.

Mod Pathol. 1996 Feb;9(2):95-8.

PMID:
8657726
10.

Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma.

Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, Fan ST, So S.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):551-6.

11.

Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential.

Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, Qin LX, Wu WZ, Liu YK, Ye SL, Tang ZY.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8557-63.

12.

Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma.

Noguchi O, Enomoto N, Ikeda T, Kobayashi F, Marumo F, Sato C.

J Hepatol. 1996 Mar;24(3):286-92.

PMID:
8778194
13.

HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.

Schoedel KE, Tyner VZ, Kim TH, Michalopoulos GK, Mars WM.

Mod Pathol. 2003 Jan;16(1):14-21.

14.

The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.

Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W.

Dig Liver Dis. 2006 Jul;38(7):490-7. Epub 2006 Apr 14.

PMID:
16627020
15.
16.

Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis.

Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A.

Int J Oncol. 2009 Sep;35(3):477-83.

PMID:
19639168
17.

Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization.

Miyasaka Y, Enomoto N, Nagayama K, Izumi N, Marumo F, Watanabe M, Sato C.

Br J Cancer. 2001 Jul 20;85(2):228-34.

18.

Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.

Osada S, Kanematsu M, Imai H, Goshima S.

Hepatogastroenterology. 2008 Mar-Apr;55(82-83):544-9.

PMID:
18613405
19.

Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.

Seiden-Long IM, Brown KR, Shih W, Wigle DA, Radulovich N, Jurisica I, Tsao MS.

Oncogene. 2006 Jan 5;25(1):91-102.

PMID:
16158056
20.

Functional genomics of hepatocellular carcinoma.

Thorgeirsson SS, Lee JS, Grisham JW.

Hepatology. 2006 Feb;43(2 Suppl 1):S145-50. Review.

PMID:
16447291

Supplemental Content

Support Center